Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection-Reference-Cited by-同舟云学术

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Published:2022-10 Issue:15 Volume:82 Page:1527-1538
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Khanna Sahil^ORCID,Assi Maha,Lee Christine,Yoho David,Louie Thomas,Knapple Whitfield,Aguilar Humberto,Garcia-Diaz Julia,Wang Gary P.,Berry Scott M.,Marion Joe,Su Xin,Braun Tricia,Bancke Lindy,Feuerstadt Paul

Funder

Rebiotix Inc., a Ferring Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-022-01797-x.pdf

Reference18 articles.

1. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–48.

2. Feuerstadt P, Nelson WW, Drozd EM, et al. Mortality, health care use, and costs of Clostridioides difficile infections in older adults. J Am Med Dir Assoc. 2022;23:1721-1728.e19.

3. Feuerstadt P, Nelson WW, Teigland C, et al. Clinical burden of recurrent Clostridioides difficile infection in the medicare population: a real-world claims analysis. Antimicrob Steward Healthc Epidemiol. 2022;2(1): e60.